JNK-IN-7: Selective JNK Inhibitor for MAPK Pathway and Apoptosis Research

Executive Summary: JNK-IN-7 is a highly selective, covalent inhibitor targeting JNK1, JNK2, and JNK3 with sub-nanomolar to low nanomolar potency (IC₅₀ = 1.54, 1.99, 0.75 nM, respectively) [APExBIO]. It binds Cys116 in JNK2, blocking kinase activity and downstream c-Jun phosphorylation (Miao et al., 2023). At higher concentrations (1–10 μM), JNK-IN-7 also modulates IRAK-1-Pellino 1 E3 ligase activity and can selectively influence innate immune pathways. The compound is insoluble in water/ethanol, soluble in DMSO (≥24.7 mg/mL), and must be stored at –20°C. JNK-IN-7 is widely used in MAPK signaling, apoptosis, and inflammation research, with best practices requiring fresh solution preparation and adherence to storage guidelines (APExBIO).

Biological Rationale

c-Jun N-terminal kinases (JNKs) are central mediators within the mitogen-activated protein kinase (MAPK) signaling pathway. JNKs regulate diverse cellular processes, including apoptosis, stress responses, and inflammatory signaling. The phosphorylation of c-Jun, a primary substrate, is a hallmark of JNK pathway activation (Miao et al., 2023). Dysregulation of JNK activity is implicated in various pathological states, such as neurodegeneration, cancer, and chronic inflammation.

Recent studies, including apoptosis models in bovine mammary epithelial cells (BMECs), show that JNK/ERK pathway activation is essential for pathogen-induced cell death (Miao et al., 2023). The use of a selective JNK inhibitor like JNK-IN-7 enables precise dissection of these pathways, allowing researchers to differentiate between mitochondrial- and death receptor-mediated apoptosis.

Mechanism of Action of JNK-IN-7

JNK-IN-7 is a covalent inhibitor with exceptional selectivity for JNK isoforms. The compound irreversibly binds to the cysteine residue Cys116 within the ATP-binding site of JNK2, inhibiting its kinase activity. This prevents subsequent phosphorylation of c-Jun and other downstream substrates (APExBIO). The IC₅₀ values for JNK1, JNK2, and JNK3 are 1.54 nM, 1.99 nM, and 0.75 nM, respectively, under standard in vitro kinase assay conditions (25°C, pH 7.5, 1 mM ATP).

At higher concentrations (1–10 μM), JNK-IN-7 inhibits IRAK-1 dependent E3 ligase activity of Pellino 1, a key player in Toll-like receptor (TLR) signaling. This dual activity enables selective modulation of innate immune responses, as demonstrated in human IL-1R cells and RAW264.7 macrophage models (APExBIO). The mechanism supports targeted investigation of inflammation and immune signaling cascades.

Evidence & Benchmarks

• JNK-IN-7 exhibits sub-nanomolar to low-nanomolar IC₅₀ against JNK isoforms (JNK1: 1.54 nM, JNK2: 1.99 nM, JNK3: 0.75 nM) in cell-free biochemical assays under standard buffer conditions (pH 7.5, 25°C) (APExBIO).
• In BMEC models, selective JNK inhibition prevents C. krusei-induced apoptosis mediated via the JNK/ERK pathway, as shown by decreased c-Jun phosphorylation and reduced TUNEL-positive cells (Miao et al., 2023).
• IC₅₀ values were determined using recombinant kinase assays with 1 mM ATP, 10 μM peptide substrate, and 30 min incubation at 25°C (APExBIO).
• JNK-IN-7 is soluble at concentrations ≥24.7 mg/mL in DMSO, but insoluble in water and ethanol. All solubility data are based on visual inspection and HPLC quantification at 25°C (APExBIO).
• At concentrations of 1–10 μM, JNK-IN-7 inhibits IRAK-1–Pellino 1 E3 ligase activity, modulating TLR signaling in RAW264.7 macrophages, as validated by immunoblotting and E3 ligase assays (APExBIO).

This article extends prior reviews such as "JNK-IN-7: Selective JNK Inhibitor for Advanced MAPK Pathw…" by focusing on new evidence from apoptosis models and clarifying selectivity details. For a deeper mechanistic discussion, see "JNK-IN-7: Selective JNK Inhibitor for MAPK Signaling and…"; in contrast, this article provides updated solubility and workflow information for experimentalists.

Applications, Limits & Misconceptions

JNK-IN-7 is widely used in:

• MAPK Signaling Pathway Research: Enables precise inhibition of c-Jun phosphorylation, clarifying MAPK cascade mechanisms.
• Apoptosis Assays: Dissects JNK-dependent versus mitochondrial or receptor-mediated apoptosis.
• Innate Immune Signaling Modulation: Investigates TLR/IRAK/Pellino axes in immune response regulation.
• Inflammation Research: Models chronic inflammation and pathogen-induced signaling in mammalian and cell line systems.

Common Pitfalls or Misconceptions

• JNK-IN-7 is not effective in water- or ethanol-based buffers due to poor solubility; always use DMSO for stock solutions (APExBIO).
• The compound loses potency if stored in solution long-term; prepare fresh solutions before each experiment.
• JNK-IN-7 does not inhibit non-JNK MAPKs (e.g., ERK, p38) at recommended concentrations (APExBIO).
• The dual activity on Pellino 1 E3 ligase is only observed at higher micromolar doses; for pure JNK inhibition, use nanomolar ranges.
• Not suitable for in vivo use without dose optimization and pharmacokinetics studies; evidence is limited to in vitro and cell culture models.

Workflow Integration & Parameters

For optimal results with JNK-IN-7 (SKU A3519, APExBIO):

• Storage: Solid form at –20°C; avoid repeated freeze–thaw cycles.
• Solubility: Dissolve in DMSO to ≥24.7 mg/mL; vortex and sonicate if needed. Filter sterilize if required.
• Working Concentrations: For kinase and signaling assays, use 0.1–100 nM for JNK inhibition; for IRAK-1/Pellino 1 studies, 1–10 μM.
• Experimental Design: Always include appropriate DMSO vehicle controls; verify phosphorylation status of c-Jun or downstream markers by immunoblotting.
• Solution Stability: Prepare fresh solutions before each experiment; do not store diluted stocks.
• For practical troubleshooting and protocol guidance, see "JNK-IN-7 (SKU A3519): Data-Driven Solutions in MAPK and A…". This article updates those recommendations with recent stability and benchmark data.

Conclusion & Outlook

JNK-IN-7, provided by APExBIO, is a benchmark tool for dissecting JNK-dependent signaling in apoptosis, inflammation, and immune modulation. Its covalent binding mechanism and selectivity allow for precise pathway interrogation. Ongoing studies continue to expand its translational relevance, particularly in inflammation research and pathogen-host interaction models. For further reading on translational perspectives, see "Translational Horizons in JNK Pathway Modulation"; this article delivers updated experimental and workflow detail for bench research. Explore the full product dossier and ordering information at APExBIO JNK-IN-7 (SKU A3519).